Galectin Therapeutics (GALT)

Executive Summary

Galectin Therapeutics is a clinical-stage biotechnology company developing belapectin (GR-MD-02), a first-in-class galectin-3 inhibitor targeting fibrosis, inflammation, and immune evasion. The company focuses on MASH cirrhosis—a leading cause of liver transplant with no approved therapies—and oncology. Despite promising preclinical data, the clinical pipeline has faced setbacks. The most advanced study, a Phase 2/3 trial of belapectin for prevention of esophageal varices in NASH cirrhosis (NCT04365868), was terminated in April 2025. Earlier Phase 1 and 2 trials in hepatic impairment, portal hypertension, psoriasis, and combination cancer therapies have been completed or terminated, with no clearly defined registrational path.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new clinical development strategy for belapectin40% success
• H2 2026Partnership or licensing deal for belapectin in MASH or oncology30% success
• Q4 2026Publication of preclinical data supporting belapectin in combination immunotherapy60% success